Literature DB >> 12818723

Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors.

Hans O Kalkman1, Dominik Feuerbach, Erika Lötscher, Philippe Schoeffter.   

Abstract

Iloperidone has demonstrated an interesting monoamine receptor profile in radioligand binding studies, with nanomolar affinity for certain noradrenaline, dopamine, and serotonin receptors. In this study, the agonist/antagonist activity of iloperidone was determined in cell lines expressing recombinant human D(2A), D(3), alpha(2C), 5-HT(1A), or 5-HT(6) receptors. With the exception of 5-HT(6) receptors, these receptors are negatively coupled to cyclase. Thus, after stimulation with forskolin, the agonists dopamine (at D(2A) and D(3)), noradrenaline (at alpha(2C)), or 8-OH-DPAT (at 5-HT(1A)) induced a reduction in cAMP accumulation. Conversely, activation of the 5-HT(6) receptor by 5-HT led to an increase in cAMP accumulation. Iloperidone alone was devoid of significant agonist activity but inhibited the agonist response in all 5 cell lines in a surmountable and concentration-dependent fashion. Iloperidone was most potent at D(3) receptors (pK(B) 8.59 +/- 0.20; n = 6), followed by alpha(2C) (pK(B) 7.83 +/- 0.06; n = 15), 5-HT(1A) (pK(B) 7.69 +/- 0.18; n = 10), D(2A) (pK(B) 7.53 +/- 0.04; n = 11) and 5-HT(6) (pK(B) 7.11 +/- 0.08; n = 11) receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818723     DOI: 10.1016/s0024-3205(03)00419-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

Review 1.  Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management.

Authors:  Michael Levine; Anne-Michelle Ruha
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  Newer oral atypical antipsychotic agents: a review.

Authors:  Jonathan R Scarff; David A Casey
Journal:  P T       Date:  2011-12

Review 3.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 4.  Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients.

Authors:  Jeffrey Rado; Philip G Janicak
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

5.  Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis.

Authors:  Qi Pei; Lu Huang; Jie Huang; Jing-Kai Gu; Yun Kuang; Xiao-Cong Zuo; Jun-Jie Ding; Hong-Yi Tan; Cheng-Xian Guo; Shi-Kun Liu; Guo-Ping Yang
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

Review 6.  New atypical antipsychotics for schizophrenia: iloperidone.

Authors:  Silvio Caccia; Luca Pasina; Alessandro Nobili
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

7.  Serotonin 1A receptor agonist increases species- and region-selective adult CNS proliferation, but not through CNTF.

Authors:  Sheila A Arnold; Theo Hagg
Journal:  Neuropharmacology       Date:  2012-08-05       Impact factor: 5.250

Review 8.  Iloperidone: in schizophrenia.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2009-10       Impact factor: 5.749

Review 9.  Long-term efficacy and safety of iloperidone: an update.

Authors:  Jeffrey T Rado; Philip G Janicak
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-26       Impact factor: 2.570

10.  Iloperidone-induced ejaculatory dysfunction: A case series.

Authors:  Niraj Narendra Ravani; Pramod H Katke
Journal:  Indian J Psychiatry       Date:  2016 Jan-Mar       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.